Topic

Articles

The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.

N4 Pharma and SRI to Collaborate on Intracellular Delivery to Specific Target Cells

Feliza Mirasol is the science editor for 

Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.

Charles River to Provide pDNA Manufacturing Services in Two Deals

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy 

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio

AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion 

Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

Editor of Pharmaceutical Technology Europe

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Bio/Pharma Business